Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts

BACKGROUND: Systemic chemotherapy with gemcitabine and cisplatin is standard of care for patients with metastatic urothelial bladder cancer. However, resistance formation is common after initial response. The protein Src is known as a proto-oncogene, which is overexpressed in various human cancers....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMC Res Notes
Hauptverfasser: Vallo, Stefan, Michaelis, Martin, Gust, Kilian M., Black, Peter C., Rothweiler, Florian, Kvasnicka, Hans-Michael, Blaheta, Roman A., Brandt, Maximilian P., Wezel, Felix, Haferkamp, Axel, Cinatl, Jindrich
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2016
Schlagworte:
Research Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5039786/
https://ncbi.nlm.nih.gov/pubmed/27677700
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13104-016-2256-3
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge